Agios Pharmaceuticals Inc (NASDAQ:AGIO) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.
A number of other brokerages have also recently commented on AGIO. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $61.00 price target on shares of Agios Pharmaceuticals in a research report on Tuesday, April 18th. Zacks Investment Research cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 18th. Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 18th. Cann reaffirmed a “buy” rating and set a $75.00 price target on shares of Agios Pharmaceuticals in a research report on Wednesday, April 19th. Finally, Oppenheimer Holdings Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, February 16th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Agios Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $63.34.
Agios Pharmaceuticals (AGIO) opened at 48.72 on Friday. The company’s market cap is $2.35 billion. The firm has a 50-day moving average price of $49.58 and a 200-day moving average price of $49.61. Agios Pharmaceuticals has a 12-month low of $35.84 and a 12-month high of $67.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.80) by $0.24. Agios Pharmaceuticals had a negative return on equity of 53.39% and a negative net margin of 341.56%. The company had revenue of $10.51 million during the quarter, compared to analysts’ expectations of $9.65 million. During the same quarter in the previous year, the firm posted ($0.64) EPS. The firm’s revenue was down 66.4% compared to the same quarter last year. On average, analysts forecast that Agios Pharmaceuticals will post ($6.44) earnings per share for the current fiscal year.
In related news, major shareholder Celgene European Investment Co acquired 624,575 shares of the firm’s stock in a transaction dated Monday, April 24th. The stock was acquired at an average price of $49.50 per share, with a total value of $30,916,462.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO David P. Schenkein sold 3,000 shares of the business’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $58.62, for a total value of $175,860.00. Following the completion of the transaction, the chief executive officer now directly owns 3,000 shares of the company’s stock, valued at approximately $175,860. The disclosure for this sale can be found here. In the last three months, insiders sold 25,782 shares of company stock valued at $1,397,902. Insiders own 10.55% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. C WorldWide Group Holding A S acquired a new position in shares of Agios Pharmaceuticals during the first quarter valued at $105,000. Bank of Montreal Can raised its position in shares of Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares in the last quarter. Blue Sky Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals during the first quarter valued at $129,000. Russell Investments Group Ltd. raised its position in shares of Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 1,583 shares in the last quarter. Finally, ARK Investment Management LLC acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at $190,000. 88.79% of the stock is owned by institutional investors and hedge funds. About Agios Pharmaceuticals
Receive News & Ratings for Agios Pharmaceuticals Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Agios Pharmaceuticals Inc and related companies with MarketBeat.com’s FREE daily email newsletter.